Paul Beringer • USC Profiles (original) (raw)

  1. Evaluation of Elexacaftor/Tezacaftor/Ivacaftor-Mediated Drug-Induced Liver Injury Using a Liver-On-Chip Model. Clin Transl Sci. 2025 Nov; 18(11):e70400. Shi A, Agarwal P, Liu ZX, Beringer PM. PMID: 41222452; PMCID: PMC12607282.
    View in: PubMed Mentions: Fields:
    Translation:Humans
  2. Challenges and Opportunities for Pharmacogenomics in the Care of People With Cystic Fibrosis. Pediatr Pulmonol. 2025 Oct; 60(10):e71358. McKinzie CJ, Beringer PM, Groman AS, Kam CW, Kubiak S, Litherland K, Pettit RS, Young DC, Tillman EM. PMID: 41147310.
    View in: PubMed Mentions: Fields:
  3. Quantitative Systems Toxicology Predicts Ivacaftor-Induced Oxidative Stress Contributes to CFTR Modulator Hepatotoxicity. Clin Pharmacol Ther. 2026 Jan; 119(1):208-218. Shi A, Cornwell C, Yang K, Beringer PM. PMID: 40985277; PMCID: PMC12746516.
    View in: PubMed Mentions: 1 Fields:
    Translation:Humans
  4. Evaluation of the drug interaction between rifabutin and elexacaftor/tezacaftor/ivacaftor (ETI). J Cyst Fibros. 2026 Jan; 25(1):151-157. Sanders M, Hong E, Chung PS, Rao AP, Cohn W, Beringer P. PMID: 40957819; PMCID: PMC12576919.
    View in: PubMed Mentions: Fields:
    Translation:HumansCTClinical Trials
  5. In Vitro Activity of Imipenem/Relebactam Alone and in Combination Against Cystic Fibrosis Isolates of Mycobacterium abscessus. Antibiotics (Basel). 2025 May 10; 14(5). Sanders M, Kim SW, Shinde A, Fletcher-Williams D, Quach E, Beringer P. PMID: 40426552; PMCID: PMC12108374.
    View in: PubMed Mentions:
  6. Predicting Maternal and Fetal Exposures of Elexacaftor-Tezacaftor-Ivacaftor during Pregnancy through Physiologically Based Pharmacokinetic Models. Clin Pharmacol Ther. 2025 Sep; 118(3):622-631. Hong E, Hebert MF, Fay E, Turner G, Eshaghian P, Trimble A, Chung PS, Rao AP, Beringer PM. PMID: 40323155; PMCID: PMC12353614.
    View in: PubMed Mentions: Fields:
    Translation:Humans
  7. Evaluation of Complex Drug Interactions Between Elexacaftor-Tezacaftor-Ivacaftor and Statins Using Physiologically Based Pharmacokinetic Modeling. Pharmaceutics. 2025 Mar 01; 17(3). Hong E, Chung PS, Rao AP, Beringer PM. PMID: 40142982; PMCID: PMC11945117.
    View in: PubMed Mentions:
  8. Pharmacokinetics of Omadacycline in Adults with Cystic Fibrosis. Clin Pharmacokinet. 2024 Dec; 63(12):1701-1709. Sanders M, Hong E, Chung PS, Rao AP, Beringer P. PMID: 39581957; PMCID: PMC11649715.
    View in: PubMed Mentions: 1 Fields:
    Translation:HumansCTClinical Trials
  9. Immunomodulatory activity of omadacycline in vitro and in a murine model of acute lung injury. mSphere. 2024 Nov 21; 9(11):e0067124. Sanders M, Beringer P. PMID: 39475317; PMCID: PMC11580420.
    View in: PubMed Mentions: 4 Fields:
    Translation:HumansAnimalsCells
  10. Development of a cystic fibrosis population model for physiologically based pharmacokinetic models: Is it worth it? CPT Pharmacometrics Syst Pharmacol. 2024 04; 13(4):509-510. Hong E, Beringer PM. PMID: 38511610; PMCID: PMC11015069.
    View in: PubMed Mentions: 2 Fields:
    Translation:Humans
  11. Pharmacokinetic Enhancement of Elexacaftor/Tezacaftor/Ivacaftor for Cystic Fibrosis: A Cost Reduction Strategy to Address Global Disparities in Access. Clin Pharmacol Ther. 2024 06; 115(6):1204-1207. Hong E, Zampoli M, Beringer PM. PMID: 38385853.
    View in: PubMed Mentions: 2 Fields:
    Translation:Humans
  12. Drug-induced liver injury associated with elexacaftor/tezacaftor/ivacaftor: A pharmacovigilance analysis of the FDA adverse event reporting system (FAERS). J Cyst Fibros. 2024 May; 23(3):566-572. Shi A, Nguyen H, Kuo CB, Beringer PM. PMID: 38233246.
    View in: PubMed Mentions: 11 Fields:
    Translation:Humans
  13. Preliminary evidence for sustained efficacy of CFTR modulator therapy with concomitant rifabutin administration. J Cyst Fibros. 2024 May; 23(3):519-523. Hong E, Parsons SM, Sass L, Epstein C, Chan L, Brown C, Eshaghian PH, Beringer PM. PMID: 38036321.
    View in: PubMed Mentions: 2 Fields:
    Translation:Humans
  14. Drug-drug interactions involving CFTR modulators: a review of the evidence and clinical implications. Expert Opin Drug Metab Toxicol. 2023 Apr; 19(4):203-216. Hong E, Shi A, Beringer P. PMID: 37259485.
    View in: PubMed Mentions: 8 Fields:
    Translation:Humans
  15. Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions between Elexacaftor/Tezacaftor/Ivacaftor and Tacrolimus in Lung Transplant Recipients. Pharmaceutics. 2023 May 08; 15(5). Hong E, Carmanov E, Shi A, Chung PS, Rao AP, Forrester K, Beringer PM. PMID: 37242680; PMCID: PMC10222456.
    View in: PubMed Mentions: 8
  16. Safety of elexacaftor/tezacaftor/ivacaftor dose reduction: Mechanistic exploration through physiologically based pharmacokinetic modeling and a clinical case series. Pharmacotherapy. 2023 04; 43(4):291-299. Hong E, Li R, Shi A, Almond LM, Wang J, Khudari AZ, Haddad S, Sislyan S, Angelich M, Chung PS, Rao AP, Beringer PM. PMID: 36866442.
    View in: PubMed Mentions: 9 Fields:
    Translation:Humans
  17. Physiologically Based Pharmacokinetic Modeling To Guide Management of Drug Interactions between Elexacaftor-Tezacaftor-Ivacaftor and Antibiotics for the Treatment of Nontuberculous Mycobacteria. Antimicrob Agents Chemother. 2022 11 15; 66(11):e0110422. Hong E, Almond LM, Chung PS, Rao AP, Beringer PM. PMID: 36286508; PMCID: PMC9664863.
    View in: PubMed Mentions: 7 Fields:
    Translation:HumansCells
  18. Physiologically-Based Pharmacokinetic-Led Guidance for Patients With Cystic Fibrosis Taking Elexacaftor-Tezacaftor-Ivacaftor With Nirmatrelvir-Ritonavir for the Treatment of COVID-19. Clin Pharmacol Ther. 2022 06; 111(6):1324-1333. Hong E, Almond LM, Chung PS, Rao AP, Beringer PM. PMID: 35292968; PMCID: PMC9087007.
    View in: PubMed Mentions: 15 Fields:
    Translation:Humans
  19. Preclinical Pharmacokinetics and Safety of Intravenous RTD-1. Antimicrob Agents Chemother. 2022 03 15; 66(3):e0212521. Park AYJ, Tran DQ, Schaal JB, Wang M, Selsted ME, Beringer PM. PMID: 35041507; PMCID: PMC8923172.
    View in: PubMed Mentions: 5 Fields:
    Translation:Animals
  20. Corrigendum to: Enhanced brain delivery and therapeutic activity of trastuzumab after blood-brain barrier opening by NEO100 in mouse models of brain-metastatic breast cancer. Neuro Oncol. 2021 Dec 01; 23(12):2123. Wang W, He H, Marín-Ramos NI, Zeng S, Swenson SD, Cho HY, Fu J, Beringer PM, Neman J, Chen L, Schönthal AH, Chen TC. PMID: 34519783; PMCID: PMC8643429.
    View in: PubMed Mentions: Fields:
  21. Chemical Synthesis of a Potent Antimicrobial Peptide Murepavadin Using a Tandem Native Chemical Ligation/Desulfurization Reaction. J Org Chem. 2021 11 05; 86(21):15242-15246. Chaudhuri D, Ganesan R, Vogelaar A, Dughbaj MA, Beringer PM, Camarero JA. PMID: 34641669; PMCID: PMC8935662.
    View in: PubMed Mentions: 6 Fields:
    Translation:Cells
  22. Enhanced brain delivery and therapeutic activity of trastuzumab after blood-brain barrier opening by NEO100 in mouse models of brain-metastatic breast cancer. Neuro Oncol. 2021 10 01; 23(10):1656-1667. Wang W, He H, Marín-Ramos NI, Zeng S, Swenson SD, Cho HY, Fu J, Beringer PM, Neman J, Chen L, Schönthal AH, Chen TC. PMID: 33659980; PMCID: PMC8485439.
    View in: PubMed Mentions: 18 Fields:
    Translation:HumansAnimalsCells
  23. Anti-Inflammatory Effects of RTD-1 in a Murine Model of Chronic Pseudomonas aeruginosa Lung Infection: Inhibition of NF-κB, Inflammasome Gene Expression, and Pro-IL-1β Biosynthesis. Antibiotics (Basel). 2021 Aug 26; 10(9). Dughbaj MA, Jayne JG, Park AYJ, Bensman TJ, Algorri M, Ouellette AJ, Selsted ME, Beringer PM. PMID: 34572625; PMCID: PMC8466744.
    View in: PubMed Mentions: 4
  24. Engineered Cyclotides with Potent Broad in Vitro and in Vivo Antimicrobial Activity. Chemistry. 2021 Sep 01; 27(49):12702-12708. Ganesan R, Dughbaj MA, Ramirez L, Beringer S, Aboye TL, Shekhtman A, Beringer PM, Camarero JA. PMID: 34159664; PMCID: PMC8410672.
    View in: PubMed Mentions: 8 Fields:
    Translation:HumansAnimalsCells
  25. Rhesus Theta Defensin 1 Promotes Long Term Survival in Systemic Candidiasis by Host Directed Mechanisms. Sci Rep. 2019 11 15; 9(1):16905. Basso V, Tran DQ, Schaal JB, Tran P, Eriguchi Y, Ngole D, Cabebe AE, Park AY, Beringer PM, Ouellette AJ, Selsted ME. PMID: 31729441; PMCID: PMC6858451.
    View in: PubMed Mentions: 10 Fields:
    Translation:AnimalsCells
  26. The Potential for QT Interval Prolongation with Chronic Azithromycin Therapy in Adult Cystic Fibrosis Patients. Pharmacotherapy. 2019 06; 39(6):718-723. Avedissian SN, Rhodes NJ, Ng TMH, Rao AP, Beringer PM. PMID: 31045258.
    View in: PubMed Mentions: 1 Fields:
    Translation:Humans
  27. Pharmacokinetics of Tedizolid in Plasma and Sputum of Adults with Cystic Fibrosis. Antimicrob Agents Chemother. 2018 09; 62(9). Park AYJ, Wang J, Jayne J, Fukushima L, Rao AP, D'Argenio DZ, Beringer PM. PMID: 29914949; PMCID: PMC6125567.
    View in: PubMed Mentions: 6 Fields:
    Translation:HumansCells
  28. Rhesus θ-Defensin-1 Attenuates Endotoxin-induced Acute Lung Injury by Inhibiting Proinflammatory Cytokines and Neutrophil Recruitment. Am J Respir Cell Mol Biol. 2018 03; 58(3):310-319. Jayne JG, Bensman TJ, Schaal JB, Park AYJ, Kimura E, Tran D, Selsted ME, Beringer PM. PMID: 28954201; PMCID: PMC5854954.
    View in: PubMed Mentions: 15 Fields:
    Translation:HumansAnimalsCells
  29. Suppression and resolution of autoimmune arthritis by rhesus θ-defensin-1, an immunomodulatory macrocyclic peptide. PLoS One. 2017; 12(11):e0187868. Schaal JB, Tran DQ, Subramanian A, Patel R, Laragione T, Roberts KD, Trinh K, Tongaonkar P, Tran PA, Minond D, Fields GB, Beringer P, Ouellette AJ, Gulko PS, Selsted ME. PMID: 29145473; PMCID: PMC5690597.
    View in: PubMed Mentions: 12 Fields:
    Translation:Animals
  30. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Determine Optimal Dosing of Ceftazidime-Avibactam for the Treatment of Acute Pulmonary Exacerbations in Patients with Cystic Fibrosis. Antimicrob Agents Chemother. 2017 10; 61(10). Bensman TJ, Wang J, Jayne J, Fukushima L, Rao AP, D'Argenio DZ, Beringer PM. PMID: 28784670; PMCID: PMC5610479.
    View in: PubMed Mentions: 20 Fields:
    Translation:HumansCellsCTClinical Trials
  31. Efficacy of Rhesus Theta-Defensin-1 in Experimental Models of Pseudomonas aeruginosa Lung Infection and Inflammation. Antimicrob Agents Chemother. 2017 08; 61(8). Bensman TJ, Jayne JG, Sun M, Kimura E, Meinert J, Wang JC, Schaal JB, Tran D, Rao AP, Akbari O, Selsted ME, Beringer PM. PMID: 28559270; PMCID: PMC5527632.
    View in: PubMed Mentions: 16 Fields:
    Translation:HumansAnimalsCells
  32. Subregional laminar cartilage MR spin-spin relaxation times (T2) in osteoarthritic knees with and without medial femorotibial cartilage loss - data from the Osteoarthritis Initiative (OAI). Osteoarthritis Cartilage. 2017 08; 25(8):1313-1323. Wirth W, Maschek S, Beringer P, Eckstein F. PMID: 28351705; PMCID: PMC5522340.
    View in: PubMed Mentions: 5 Fields:
    Translation:HumansCTClinical Trials
  33. Rhesus θ-defensin-1 (RTD-1) exhibits in vitro and in vivo activity against cystic fibrosis strains of Pseudomonas aeruginosa. J Antimicrob Chemother. 2016 Jan; 71(1):181-8. Beringer PM, Bensman TJ, Ho H, Agnello M, Denovel N, Nguyen A, Wong-Beringer A, She R, Tran DQ, Moskowitz SM, Selsted ME. PMID: 26433781; PMCID: PMC5007590.
    View in: PubMed Mentions: 19 Fields:
    Translation:HumansAnimalsCells
  34. Discovery of Novel CXCR2 Inhibitors Using Ligand-Based Pharmacophore Models. J Chem Inf Model. 2015 Aug 24; 55(8):1720-38. Ha H, Debnath B, Odde S, Bensman T, Ho H, Beringer PM, Neamati N. PMID: 26153616.
    View in: PubMed Mentions: 8 Fields:
    Translation:HumansAnimalsCells
  35. A novel phenylcyclohex-1-enecarbothioamide derivative inhibits CXCL8-mediated chemotaxis through selective regulation of CXCR2-mediated signalling. Br J Pharmacol. 2014 Mar; 171(6):1551-65. Ha H, Bensman T, Ho H, Beringer PM, Neamati N. PMID: 24354854; PMCID: PMC3954492.
    View in: PubMed Mentions: 6 Fields:
    Translation:AnimalsCells
  36. Doxycycline exhibits anti-inflammatory activity in CF bronchial epithelial cells. Pulm Pharmacol Ther. 2012 Oct; 25(5):377-82. Bensman TJ, Nguyen AN, Rao AP, Beringer PM. PMID: 22771903.
    View in: PubMed Mentions: 2 Fields:
    Translation:HumansCells
  37. Acute care clinical pharmacy practice: unit- versus service-based models. Pharmacotherapy. 2012 Feb; 32(2):e35-44. American College of Clinical Pharmacy, Haas CE, Eckel S, Arif S, Beringer PM, Blake EW, Lardieri AB, Lobo BL, Mercer JM, Moye P, Orlando PL, Wargo K. PMID: 22392430.
    View in: PubMed Mentions: 2 Fields:
    Translation:Humans
  38. Pharmacokinetics of doxycycline in adults with cystic fibrosis. Antimicrob Agents Chemother. 2012 Jan; 56(1):70-4. Beringer PM, Owens H, Nguyen A, Benitez D, Rao A, D'Argenio DZ. PMID: 22024822; PMCID: PMC3256044.
    View in: PubMed Mentions: 25 Fields:
    Translation:Humans
  39. Applying new diagnostic criteria for acute kidney injury to facilitate early identification of nephrotoxicity in vancomycin-treated patients. Antimicrob Agents Chemother. 2011 Jul; 55(7):3278-83. Minejima E, Choi J, Beringer P, Lou M, Tse E, Wong-Beringer A. PMID: 21576448; PMCID: PMC3122454.
    View in: PubMed Mentions: 41 Fields:
    Translation:Humans
  40. Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy. Int J Antimicrob Agents. 2011 Feb; 37(2):95-101. Wong-Beringer A, Joo J, Tse E, Beringer P. PMID: 21130609.
    View in: PubMed Mentions: 66 Fields:
    Translation:HumansCells
  41. Estimation of glomerular filtration rate by using serum cystatin C and serum creatinine concentrations in patients with human immunodeficiency virus. Pharmacotherapy. 2010 Oct; 30(10):1004-10. Beringer PM, Owens H, Nguyen A, Mordwinkin N, Louie S, Mak M, Sattler F. PMID: 20874037.
    View in: PubMed Mentions: 10 Fields:
    Translation:HumansCells
  42. Recommended education for pharmacists as competitive clinical scientists. Pharmacotherapy. 2009 Feb; 29(2):236-44. Dowling TC, Murphy JE, Kalus JS, Nkansah NT, Chappell JS, Wiederhold NP, Beringer P, Crews KR, Grabinski JL, Evens RP, Leff R, American College of Clinical Pharmacy. PMID: 19170592.
    View in: PubMed Mentions: 12 Fields:
    Translation:Humans
  43. GFR estimates using cystatin C are superior to serum creatinine in adult patients with cystic fibrosis. J Cyst Fibros. 2009 Jan; 8(1):19-25. Beringer PM, Hidayat L, Heed A, Zheng L, Owens H, Benitez D, Rao AP. PMID: 18799365.
    View in: PubMed Mentions: 17 Fields:
    Translation:Humans
  44. Lack of effect of P-glycoprotein inhibition on renal clearance of dicloxacillin in patients with cystic fibrosis. Pharmacotherapy. 2008 Jul; 28(7):883-94. Beringer PM, Kriengkauykiat J, Zhang X, Hidayat L, Liu S, Louie S, Synold T, Burckart GJ, Rao PA, Shapiro B, Gill M. PMID: 18576903.
    View in: PubMed Mentions: 5 Fields:
    Translation:Humans
  45. Probenecid, but not cystic fibrosis, alters the total and renal clearance of fexofenadine. J Clin Pharmacol. 2008 Aug; 48(8):957-65. Liu S, Beringer PM, Hidayat L, Rao AP, Louie S, Burckart GJ, Shapiro B. PMID: 18511651.
    View in: PubMed Mentions: 9 Fields:
    Translation:HumansCellsCTClinical Trials
  46. Pilot study of continuous infusion cefepime in adult patients with cystic fibrosis. J Antimicrob Chemother. 2006 May; 57(5):1017-9. Han EE, Beringer PM, Falck P, Louie S, Rao P, Shapiro B, Gill M. PMID: 16533828.
    View in: PubMed Mentions: 8 Fields:
    Translation:Humans
  47. Absolute bioavailability and intracellular pharmacokinetics of azithromycin in patients with cystic fibrosis. Antimicrob Agents Chemother. 2005 Dec; 49(12):5013-7. Beringer P, Huynh KM, Kriengkauykiat J, Bi L, Hoem N, Louie S, Han E, Nguyen T, Hsu D, Rao PA, Shapiro B, Gill M. PMID: 16304166; PMCID: PMC1315964.
    View in: PubMed Mentions: 23 Fields:
    Translation:Humans
  48. Suitability of caspofungin for aerosol delivery: physicochemical profiling and nebulizer choice. Chest. 2005 Nov; 128(5):3711-6. Wong-Beringer A, Lambros MP, Beringer PM, Johnson DL. PMID: 16304338.
    View in: PubMed Mentions: 5 Fields:
    Translation:Humans
  49. Absolute bioavailability and pharmacokinetics of linezolid in hospitalized patients given enteral feedings. Antimicrob Agents Chemother. 2005 Sep; 49(9):3676-81. Beringer P, Nguyen M, Hoem N, Louie S, Gill M, Gurevitch M, Wong-Beringer A. PMID: 16127039; PMCID: PMC1195442.
    View in: PubMed Mentions: 24 Fields:
    Translation:HumansCTClinical Trials
  50. Transporters and their impact on drug disposition. Ann Pharmacother. 2005 Jun; 39(6):1097-108. Beringer PM, Slaughter RL. PMID: 15886292.
    View in: PubMed Mentions: 10 Fields:
    Translation:Humans
  51. Phase I clinical and pharmacokinetic trial of docetaxel and irinotecan administered on a weekly schedule. Cancer Chemother Pharmacol. 2005 Jul; 56(1):75-82. Garcia AA, Pujari M, Jeffers S, Iqbal S, Lenz HJ, Beringer P, Louie S. PMID: 15809878.
    View in: PubMed Mentions: 2 Fields:
    Translation:HumansCTClinical Trials
  52. A comparison of phenytoin-loading techniques in the emergency department. Acad Emerg Med. 2004 Mar; 11(3):244-52. Swadron SP, Rudis MI, Azimian K, Beringer P, Fort D, Orlinsky M. PMID: 15001403.
    View in: PubMed Mentions: 15 Fields:
    Translation:HumansCTClinical Trials
  53. Pharmacokinetics of Ibuprofen in children with cystic fibrosis. Clin Pharmacokinet. 2004; 43(3):145-56. Han EE, Beringer PM, Louie SG, Gill MA, Shapiro BJ. PMID: 14871154.
    View in: PubMed Mentions: 3 Fields:
    Translation:Humans
  54. Stability and antibacterial activity of cefepime during continuous infusion. Antimicrob Agents Chemother. 2003 Jun; 47(6):1991-4. Sprauten PF, Beringer PM, Louie SG, Synold TW, Gill MA. PMID: 12760882; PMCID: PMC155835.
    View in: PubMed Mentions: 9 Fields:
    Translation:Cells
  55. Potential role of macrolide antibiotics in the management of cystic fibrosis lung disease. Curr Opin Pulm Med. 2002 Nov; 8(6):521-8. Nguyen T, Louie SG, Beringer PM, Gill MA. PMID: 12394161.
    View in: PubMed Mentions: 9 Fields:
    Translation:HumansCells
  56. Distribution and elimination of tobramycin administered in single or multiple daily doses in adult patients with cystic fibrosis. J Antimicrob Chemother. 2002 Oct; 50(4):553-9. Aminimanizani A, Beringer PM, Kang J, Tsang L, Jelliffe RW, Shapiro BJ. PMID: 12356801.
    View in: PubMed Mentions: 18 Fields:
    Translation:Humans
  57. Development of population pharmacokinetic models and optimal sampling times for ibuprofen tablet and suspension formulations in children with cystic fibrosis. Ther Drug Monit. 2002 Apr; 24(2):315-21. Beringer P, Aminimanizani A, Synold T, Scott C. PMID: 11897978.
    View in: PubMed Mentions: 3 Fields:
    Translation:Humans
  58. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis. Antimicrob Agents Chemother. 2001 Dec; 45(12):3468-73. Montgomery MJ, Beringer PM, Aminimanizani A, Louie SG, Shapiro BJ, Jelliffe R, Gill MA. PMID: 11709326; PMCID: PMC90855.
    View in: PubMed Mentions: 17 Fields:
    Translation:HumansCellsCTClinical Trials
  59. The clinical use of colistin in patients with cystic fibrosis. Curr Opin Pulm Med. 2001 Nov; 7(6):434-40. Beringer P. PMID: 11706322.
    View in: PubMed Mentions: 42 Fields:
    Translation:HumansCells
  60. Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials. Clin Pharmacokinet. 2001; 40(3):169-87. Aminimanizani A, Beringer P, Jelliffe R. PMID: 11327197.
    View in: PubMed Mentions: 32 Fields:
    Translation:Humans
  61. Estimation of creatinine clearance in patients with metastatic ovarian cancer. Ther Drug Monit. 2000 Dec; 22(6):695-700. Montgomery MJ, Beringer PM, Louie SG, Gill MA. PMID: 11128237.
    View in: PubMed Mentions: 2 Fields:
    Translation:Humans
  62. Unusual respiratory bacterial flora in cystic fibrosis: microbiologic and clinical features. Curr Opin Pulm Med. 2000 Nov; 6(6):545-50. Beringer PM, Appleman MD. PMID: 11100967.
    View in: PubMed Mentions: 16 Fields:
    Translation:HumansCells
  63. Pharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administration. Antimicrob Agents Chemother. 2000 Apr; 44(4):809-13. Beringer PM, Vinks AA, Jelliffe RW, Shapiro BJ. PMID: 10722474; PMCID: PMC89775.
    View in: PubMed Mentions: 18 Fields:
    Translation:HumansCTClinical Trials
  64. New approaches to optimizing antimicrobial therapy in patients with cystic fibrosis. Curr Opin Pulm Med. 1999 Nov; 5(6):371-7. Beringer PM. PMID: 10570739.
    View in: PubMed Mentions: 3 Fields:
    Translation:Humans
  65. Predictive performance of a vancomycin-aminoglycoside population model. Ann Pharmacother. 1998 Feb; 32(2):176-81. Beringer PM, Wong-Beringer A, Rho JP. PMID: 9496400.
    View in: PubMed Mentions: 3 Fields:
    Translation:Humans
  66. Economic aspects of antibacterial adverse effects. Pharmacoeconomics. 1998 Jan; 13(1 Pt 1):35-49. Beringer PM, Wong-Beringer A, Rho JP. PMID: 10175984.
    View in: PubMed Mentions: 18 Fields:
    Translation:Humans
  67. Pharmacokinetics of once-daily amikacin dosing in patients with cystic fibrosis. J Antimicrob Chemother. 1998 Jan; 41(1):142-4. Beringer PM, Vinks AA, Jelliffe RW. PMID: 9511054.
    View in: PubMed Mentions: 1 Fields:
    Translation:Humans
  68. Successful treatment of multidrug-resistant Pseudomonas aeruginosa meningitis with high-dose ciprofloxacin. Clin Infect Dis. 1997 Oct; 25(4):936-7. Wong-Beringer A, Beringer P, Lovett MA. PMID: 9356822.
    View in: PubMed Mentions: 5 Fields:
    Translation:HumansCells
  69. Is routine measurement of free phenytoin concentrations rational? Ther Drug Monit. 1995 Aug; 17(4):381-2. Beringer PM, Rho JP. PMID: 7482694.
    View in: PubMed Mentions: 1 Fields:
    Translation:Humans

Start with: newest oldestInclude: line numbers double spacing all authors publication IDs